BLADDER- PRESERVING STRATEGIES IN UROTHELIAL CANCER FOLLOWED BY SYSTEMIC RELAPSE

Bernadett Szabados
Barts Cancer Institute, St Bartholomew's Hospital
London, United Kingdom
DISCLOSURES

Travel, research funding: Roche, Genentech
Invited lecture: Merck
• 57 years, male, retired soldier
• Paraplegic due to spontaneous spinal epidural hematoma
• Ex-smoker

Jan 2016

HAEMATURIA

Cystoscopy
CT IVU

CT, computed tomography; IVU, intravenous urogram
• 57 years, male, paraplegic
• ECOG 1
• Creatinine clearance > 60mL/min

Jan 2016
HAEMATURIA

Cystoscopy
CT IVU

March 2016
TURBT

TCC
pT2 HG

CT, computed tomography; HG, high-grade; IVU, intravenous urogram; TCC, transitional cell carcinoma; TURBT, transurethral resection of bladder tumour
Question 1

Treatment options?

1. Radical cystectomy

2. Neoadjuvant chemotherapy + cystectomy

3. Chemo-radiotherapy

4. Neoadjuvant chemotherapy + chemo-radiotherapy

Choose one option
- 57 years, male, paraplegic
- pT2 N0 M0
- ECOG 1
- Creatinine clearance > 60mL/min

Jan 2016

Haematuria

Cystoscopy
CT IVU

March 2016

MIBC

TCC
pT2 HG

CT, computed tomography; HG, high-grade; IVU, intravenous urogram; TCC, transitional cell carcinoma; MIBC, muscle-invasive bladder cancer
• 57 years, male, paraplegic
• pT2 N0 M0
• NAC + chemo/rad
• ECOG 2
• Bajorin: 1 risk factor

Jan 2016

Cystoscopy
CT IVU

March 2016

HAEMATURIA

MIBC

NAC
Chemo-rad

Jan 2018

CT, computed tomography; ECOG, Eastern Cooperative Oncology Group; IVU, intravenous urogram; MIBC, muscle-invasive bladder cancer; NAC, neoadjuvant chemotherapy
Question 2

Treatment options?

1. Test for PD – L1 → + : immune checkpoint inhibitors
   → - : carboplatin – based chemotherapy

2. Immune checkpoint inhibitors

3. Carboplatin – based chemotherapy

4. Palliative care
- 57 years, male, paraplegic
- pT2 N0 M0
- ECOG 2
- Bajorin: 1 risk factor

Jan 2016

HAEMATURIA

Cystoscopy
CT IVU

March 2016

MIBC
NAC Chemo-rad

Jan 2018

1st LINE

Pembrolizumab

2019

Must be PDL-1 positive

CT, computed tomography; ECOG, Eastern Cooperative Oncology Group; IVU, intravenous urogram; MIBC, muscle-invasive bladder cancer; NAC, neoadjuvant chemotherapy; Bajorin prognostic factors
PEMBROLIZUMAB
- 11 cycles
- Partial Response
- Toxicities: hypothyroidism → substitution therapy
• 57 years, male, paraplegic
• pT2 N0 M0
• ECOG 2
• Bellmunt: 1 risk factor

<table>
<thead>
<tr>
<th>Jan 2016</th>
<th>March 2016</th>
<th>Jan 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>HAEMATURIA</td>
<td>MIBC</td>
<td>1st LINE</td>
</tr>
<tr>
<td>Cystoscopy</td>
<td>NAC Chemo-rad</td>
<td>Pembrolizumab</td>
</tr>
<tr>
<td>CT IVU</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ECOG, Eastern Cooperative Oncology Group; NAC, neoadjuvant chemotherapy
Question 3

Treatment options?

1. MVAC
2. Gemcitabine / Cisplatin
3. Gemcitabine/Carboplatin
4. Docetaxel
5. Vinflunine
6. Palliative care

Choose one option

MVAC, methotrexate, vinblastine, doxorubicin and cisplatin
- 57 years, male, paraplegic
- pT2 N0 M0
- ECOG 2
- Bellmunt: 1 risk factor

Jan 2016
HAEMATURIA
Cystoscopy
CT IVU

March 2016
MIBC
NAC Chemo-rad

Jan 2018
1st LINE
Pembrolizumab

Aug 2018
2nd LINE
Gemcitabine/Carboplatin

CT, computed tomography; ECOG, Eastern Cooperative Oncology Group; IVU, intravenous urogram; MIBC, muscle-invasive bladder cancer; NAC, neoadjuvant chemotherapy; Bellmunt risk factors
GEMCITABINE / CARBOPLATIN

- 5 cycles
- Stable Disease
- Toxicities: thrombopenia
- 57 years, male, paraplegic
- pT2 N0 M0
- ECOG 2

Jan 2019

Jan 2018
- Pembrolizumab

March 2016
- MIBC
- NAC Chemo-rad

HAEMATURIA
- Cystoscopy
- CT IVU

Aug 2018
- 2nd LINE
- Gemcitabine/Carboplatin

Jan 2016
- 1st LINE

CT, computed tomography; ECOG, Eastern Cooperative Oncology Group; IVU, intravenous urogram; MIBC, muscle-invasive bladder cancer; NAC, neoadjuvant chemotherapy
Question 4

Treatment options?

1. Gemcitabine / Cisplatin
2. Docetaxel
3. Enfortumab Vedotin
4. Vinflunine
5. ICI re-challenge
6. FGFR – testing
7. Palliative care
8. Clinical trials

Choose one option
- 57 years, male, paraplegic
- pT2 N0 M0
- ECOG 2

**Jan 2016**
- HAEMATURIA
  - Cystoscopy
  - CT IVU

**March 2016**
- MIBC
  - NAC Chemo-rad

**Jan 2018**
- 1st LINE
  - Pembrolizumab

**Aug 2018**
- 2nd LINE
  - Gemcitabine/Carboplatin

**Jan 2019**
- 3rd LINE
  - Enfortumab Vedotin *

CT, computed tomography; ECOG, Eastern Cooperative Oncology Group; IVU, intravenous urogram; MIBC, muscle-invasive bladder cancer; NAC, neoadjuvant chemotherapy; * NCT03474107
Thank you